Adjuvant {beta}-lactam therapy combined with vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: Does {beta}-lactam class matter? [Clinical Therapeutics]

We analyzed the impact of vancomycin (VAN) combined with adjuvant β-lactam therapy (COMBO) on persistent methicillin-resistant Staphylococcus aureus bacteremia (≥5 days) compared to VAN using pooled data from two previously published, observational studies (n=156). COMBO was inversely associated with persistent bacteremia (adjusted odds ratio 0.460, 95% confidence interval, 0.229-0.923). Acute kidney injury was more common in COMBO than VAN (18.9% and 7.6%, respectively; p=0.062).

http://bit.ly/2Ay0dDS